 | Up a level |
2020
Bendell, Johanna C., Bischoff, Helge G., Hwang, Jimmy, Reinhardt, Hans Christian, Zander, Thomas, Wang, Xuejing, Hynes, Scott, Pitou, Celine, Campbell, Robert, Iversen, Philip, Farrington, Daphne L., Bell-McGuinn, Katherine and Thomas, Michael (2020). A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer. Invest. New Drugs, 38 (4). S. 1145 - 1156. DORDRECHT: SPRINGER. ISSN 1573-0646
2019
Munster, Pamela, Mita, Monica, Mahipal, Amit, Nemunaitis, John, Massard, Christophe, Mikkelsen, Tom, Cruz, Cristina, Paz-Ares, Luis, Hidalgo, Manuel, Rathkopf, Dana, Blumenschein, George, Jr., Smith, David C., Eichhorst, Barbara, Cloughesy, Tim, Filvaroff, Ellen H., Li, Shaoyi, Raymon, Heather, de Haan, Hans, Hege, Kristen and Bendell, Johanna C. (2019). First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy. Cancer Manag. Res., 11. S. 10463 - 10477. ALBANY: DOVE MEDICAL PRESS LTD. ISSN 1179-1322
2016
Munster, Pamela N., Mahipal, Amit, Nemunaitis, John J., Mita, Monica M., Paz-Ares, Luis G., Massard, Christophe, Mikkelsen, Tom, Cruz, Cristina, Rathkopf, Dana E., Blumenschein, George R., Hidalgo, Manuel, Smith, David C., Eichhorst, Barbara, Cloughesy, Timothy Francis, Garrick, Brett, Trowe, Torsten, Filvaroff, Ellen, Hege, Kristen and Bendell, Johanna C. (2016). Phase I trial of a dual TOR kinase and DNA-PK inhibitor (CC-115) in advanced solid and hematologic cancers. J. Clin. Oncol., 34 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755